Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

Clinical trial NCT04649723 · COMPLETED

Trial details

NCT number: NCT04649723
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

Start date: 2020-11-24
Primary completion: 2020-12-14
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.